Botulinum neurotoxin and chronic migraine: muscle fiber chemodenervation or nociceptic system modulation?

The results of controlled investigations suggest that botulinumtoxin type A (BTA) leads to decrease headache intensity and prevent migraine attacks. The antinociceptive mechanisms of BTA action remain unclear. Modern and previous hypothesis of antinociceptive action BTA in chronic migraine (CM) are...

Full description

Bibliographic Details
Main Authors: A. R. Artemenko, A. L. Kurenkov, S. S. Nikitin, K. B. Belomestova
Format: Article
Language:Russian
Published: ABV-press 2015-02-01
Series:Нервно-мышечные болезни
Subjects:
Online Access:https://nmb.abvpress.ru/jour/article/view/61
_version_ 1797702916051566592
author A. R. Artemenko
A. L. Kurenkov
S. S. Nikitin
K. B. Belomestova
author_facet A. R. Artemenko
A. L. Kurenkov
S. S. Nikitin
K. B. Belomestova
author_sort A. R. Artemenko
collection DOAJ
description The results of controlled investigations suggest that botulinumtoxin type A (BTA) leads to decrease headache intensity and prevent migraine attacks. The antinociceptive mechanisms of BTA action remain unclear. Modern and previous hypothesis of antinociceptive action BTA in chronic migraine (CM) are discussed in details. Recent experimental and clinical evidence strongly suggest that BTA has aspecific antinociceptive effect realized through inhibition of proinflammatory neurotransmitters release not only from the sensory terminals but from muscle nociceptors. The mechanism of the action of BTA in CM has more than one target and is considered to involve different pathophysiological levels CM: neurogenic inflammation, peripheral and central sensitization. The administration of BTA on the PREEMPT principle (paradigm) ensures optimal neurotoxin distribution in the anatomic areas in accordance with their sensory innervation by cervical segments and sensory fibers in the trigeminal system, the terminal branches which are the major target of BTA in the treatment of CM.
first_indexed 2024-03-12T04:56:51Z
format Article
id doaj.art-8e8e289410fb4e21b5211485aac18d39
institution Directory Open Access Journal
issn 2222-8721
2413-0443
language Russian
last_indexed 2024-03-12T04:56:51Z
publishDate 2015-02-01
publisher ABV-press
record_format Article
series Нервно-мышечные болезни
spelling doaj.art-8e8e289410fb4e21b5211485aac18d392023-09-03T09:14:51ZrusABV-pressНервно-мышечные болезни2222-87212413-04432015-02-010461210.17650/2222-8721-2013-0-4-6-1255Botulinum neurotoxin and chronic migraine: muscle fiber chemodenervation or nociceptic system modulation?A. R. Artemenko0A. L. Kurenkov1S. S. Nikitin2K. B. Belomestova3ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова»ФГБУ «Научный центр здоровья детей» РАМННИИ общей патологии и патофизиологии РАМН, МоскваГБОУ ВПО «Первый МГМУ им. И.М. Сеченова»The results of controlled investigations suggest that botulinumtoxin type A (BTA) leads to decrease headache intensity and prevent migraine attacks. The antinociceptive mechanisms of BTA action remain unclear. Modern and previous hypothesis of antinociceptive action BTA in chronic migraine (CM) are discussed in details. Recent experimental and clinical evidence strongly suggest that BTA has aspecific antinociceptive effect realized through inhibition of proinflammatory neurotransmitters release not only from the sensory terminals but from muscle nociceptors. The mechanism of the action of BTA in CM has more than one target and is considered to involve different pathophysiological levels CM: neurogenic inflammation, peripheral and central sensitization. The administration of BTA on the PREEMPT principle (paradigm) ensures optimal neurotoxin distribution in the anatomic areas in accordance with their sensory innervation by cervical segments and sensory fibers in the trigeminal system, the terminal branches which are the major target of BTA in the treatment of CM.https://nmb.abvpress.ru/jour/article/view/61хроническая мигреньботулинический токсин типа аоnabotulinumtoxinaхемоденервацияантиноцицептивное действиекалицитонин-генсвязанный пептиднейрогенное воспалениепериферическая сенситизацияцентральная сенситизация
spellingShingle A. R. Artemenko
A. L. Kurenkov
S. S. Nikitin
K. B. Belomestova
Botulinum neurotoxin and chronic migraine: muscle fiber chemodenervation or nociceptic system modulation?
Нервно-мышечные болезни
хроническая мигрень
ботулинический токсин типа а
оnabotulinumtoxina
хемоденервация
антиноцицептивное действие
калицитонин-генсвязанный пептид
нейрогенное воспаление
периферическая сенситизация
центральная сенситизация
title Botulinum neurotoxin and chronic migraine: muscle fiber chemodenervation or nociceptic system modulation?
title_full Botulinum neurotoxin and chronic migraine: muscle fiber chemodenervation or nociceptic system modulation?
title_fullStr Botulinum neurotoxin and chronic migraine: muscle fiber chemodenervation or nociceptic system modulation?
title_full_unstemmed Botulinum neurotoxin and chronic migraine: muscle fiber chemodenervation or nociceptic system modulation?
title_short Botulinum neurotoxin and chronic migraine: muscle fiber chemodenervation or nociceptic system modulation?
title_sort botulinum neurotoxin and chronic migraine muscle fiber chemodenervation or nociceptic system modulation
topic хроническая мигрень
ботулинический токсин типа а
оnabotulinumtoxina
хемоденервация
антиноцицептивное действие
калицитонин-генсвязанный пептид
нейрогенное воспаление
периферическая сенситизация
центральная сенситизация
url https://nmb.abvpress.ru/jour/article/view/61
work_keys_str_mv AT arartemenko botulinumneurotoxinandchronicmigrainemusclefiberchemodenervationornocicepticsystemmodulation
AT alkurenkov botulinumneurotoxinandchronicmigrainemusclefiberchemodenervationornocicepticsystemmodulation
AT ssnikitin botulinumneurotoxinandchronicmigrainemusclefiberchemodenervationornocicepticsystemmodulation
AT kbbelomestova botulinumneurotoxinandchronicmigrainemusclefiberchemodenervationornocicepticsystemmodulation